Form 4: Revolution Medicines Executive Sells Shares Under 10b5-1 Trading Plan

Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, sold 16,667 shares of common stock at an average price of $42.9825, while also exercising options to acquire the same number of shares at $4.09.

Summary

• Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, executed transactions involving the company's common stock on August 13, 2024.
• Kelsey exercised stock options to acquire 16,667 shares at a price of $4.09 per share.
• Simultaneously, Kelsey sold 16,667 shares at a weighted average price of $42.9825, with individual sales prices ranging from $42.76 to $43.42.
• These transactions were conducted under a pre-arranged 10b5-1 trading plan adopted on March 15, 2024.
• Following these transactions, Kelsey directly owns 269,073 shares of Revolution Medicines common stock, which includes 95,476 restricted stock units.
• Kelsey also directly owns 56,665 derivative securities in the form of stock options.

Sentiment

Score: 5

Explanation: The document reflects routine executive stock transactions under a pre-arranged plan, indicating a neutral sentiment.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which can mitigate concerns about insider trading.

Risks

• Executive stock sales can sometimes be perceived negatively by investors, although the use of a 10b5-1 plan can alleviate these concerns.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies. The use of 10b5-1 trading plans is a standard practice to allow insiders to sell shares while avoiding accusations of insider trading.

Comparison to Industry Standards

• Executive compensation packages often include stock options and restricted stock units to align management's interests with those of shareholders.
• Trading activity by insiders is closely monitored and reported to the SEC via Form 4 filings.
• The use of 10b5-1 trading plans is a widespread practice among public company executives to manage their personal finances and diversify their holdings.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, depending on their perception of executive stock sales.
• The use of a 10b5-1 trading plan can reassure stakeholders that the transactions were not based on inside information.

Key Dates